Industry Alliance Program - Highlighted CIRM-Catalyzed Spinouts
CIRM's support has been instrumental to our early successes and our ability to rapidly progress Forty Seven's CD47 antibody targeting approach with magrolimab. CIRM was an early collaborator in our clinical programs and it’s support was instrumental in helping us reach a point where we could become a part of Gilead and move forward with our research.”
HIGHLIGHTED CIRM-CATALYZED SPINOUTS
CIRM funding to California academic institutions has enabled the launch of more than 40 spinout companies, some of which are highlighted below.
PUBLIC
Click on logos below to learn more
Anti-CD47 Ab immunotherapies for cancer and blood disorders
CIRM Impact: Funded discovery and preclinical development of anti-CD47 antibody at Stanford, currently funding two Forty Seven Inc. clinical trials.
Partnering Highlights: $4.9B Gilead Acquisition
CAR-T therapies for cancer and gene therapy for blood disorders
CIRM Impact: Funded discovery and preclinical development, and currently funding clinical trials, of multiple CAR-T therapies at City of Hope.
Partnering Highlights: $31.5M Public Offering (2019)
Gene therapies for immune disorders
CIRM Impact: Funding lead candidate ADA-SCID gene therapy clinical trial as well as X-CGD gene therapy trial.
Partnering Highlights: $225.5M IPO (2018)
Epigenetics research tools
CIRM Impact: Funded research in epigenetics at Stanford that enabled Epinomics launch.
Partnering Highlights: Acquired by 10X Genomics (2018)
Anti-ROR1 Ab immunotherapies for cancer
CIRM Impact: Funded discovery, preclinical and clinical development of anti-ROR1 Ab at UCSD, currently funding Oncternal’s clinical trial.
Partnering Highlights: Reverse Merger with GTX (2019)
VENTURE-BACKED
Click on logos below to learn more
Gene therapies for various disease indications
CIRM Impact: Funded directed evolution of AAV research at UC Berkeley.
Partnering Highlights: $90M Series B (2018)
WNT-based therapies for bone regeneration
CIRM Impact: Funded discovery and preclinical development of WNT-based therapy at Stanford, currently funding Ankasa’s IND-enabling studies.
Partnering Highlights: $19M Venture Financing
iPSC-based cell therapy for Parkinson’s disease
CIRM Impact: Funded iPSC research and candidate discovery at Scripps.
Partnering Highlights: $70M Series A venture financing (2020)
iPSC-based T-cell immunotherapies for cancer
CIRM Impact: Funded technology platform development and candidate discovery at Stanford.
Partnering Highlights: $250M Series A financing (2019)
Ab-based bone marrow conditioning regimen
CIRM Impact: Funded discovery and preclinical development, and currently funding clinical trial, at Stanford.
Partnering Highlights: $50M Series A financing (2020)
iPSC-based cancer vaccines & cell therapies for cardiovascular diseases
CIRM Impact: Funded candidate discovery research at Stanford.
Partnering Highlights: Funded by Leaps by Bayer (2019)
CRISPR-based RNA gene therapy
CIRM Impact: Funded technology platform development at UCSD
Partnering Highlights: $55M Series A financing (2019)
Magnetic particle imaging in living organisms
CIRM Impact: Funded technology platform development at UC Berkeley.
Partnering Highlights: Commercial
Neural cell therapies for neurological disorders
CIRM Impact: Funded research of stem cell-derived specialized neurons at UCSF, currently funding Neurona’s preclinical development of lead candidate for epilepsy.
Partnering Highlights: $28.5M Series A financing (2014); $20M Series B financing (2018); $43.5M Series C financing (2020)
ESC-based tissue engineered patch for dry AMD
CIRM Impact: Funded candidate discovery and preclinical development at USC, UCSB & Caltech and RPT’s phase 1/2a clinical trial.
Partnering Highlights: Santen Pharma partnership (2017)
In vivo gene therapy for cardiac diseases
CIRM Impact: Funded direct reprogramming and candidate discovery research at Gladstone.
Partnering Highlights: $92M Series B venture financing (2019)
Anti-ROR1 Ab based antibody drug conjugates for cancer
CIRM Impact: Funded Anti-ROR1 Ab discovery and development at UCSD.
Partnering Highlights: $58M Series A venture financing (2018)
PRIVATE
Click on logos below to learn more
Progenitor cell therapy for Retinitis Pigmentosa
CIRM Impact: Funded discovery and preclinical development at UCI, currently funding jCyte’s phase 2 clinical trials.
Partnering Highlights: $252M Santen Ex-US Licensing & Commercialization Agreement (2020)
Latest Press Releases
CIRM-funded research programs are helping turn stem cells into cures. Browse our press release archive below to find out the latest advances. For even more breaking news, visit our blog, The Stem Cellar.
-
Apr 20, 2021
-
Mar 30, 2021
-
Feb 9, 2021
-
Jan 11, 2021